Page Title
Clinical Trial Finder
Ask About Participating in This Study
Nutritional-GIEnrolling
Study to evaluate ANG003 enzyme therapy in adults with cystic fibrosis who have pancreatic insufficiency. , protocol number Anagram ANG003-22-101The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Nutritional-GIEnrolling
Study to evaluate ANG003 enzyme therapy in adults with cystic fibrosis who have pancreatic insufficiency. , protocol number Anagram ANG003-22-101
This phase 1 study will evaluate the safety, tolerability, and effectiveness of a single dose of ANG003. One dose of the study drug will be given in place of a participant's usual pancreatic enzymes.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
4
-
Length of Participation:
23 days
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More